SMIM4

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, SMIM4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SMIM4 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SMIM4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMIM4 expression acts as an unfavorable survival marker.

CESC and LIHC are the cancer types where SMIM4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
CESCOSMedianII,III,IV0.1560.759.00724view →
LIHCDFSMedianAll0.0800.553.00412view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SMIM4–CESC (OS)

Kaplan–Meier survival curve for SMIM4 mutant vs wild-type samples in CESC.

Open the CESC breakdown →

Exploration